Cabaletta Bio Financials

CABA Stock

USD 2.60 0.16 6.56%

Based on the analysis of Cabaletta Bio's profitability, liquidity, and operating efficiency, Cabaletta Bio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Cabaletta Bio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 32.7 M, whereas Total Assets are forecasted to decline to about 133.7 M.

Covid

Interest Hikes

Cabaletta Bio Balance Sheet Chart

At present, Cabaletta Bio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 32.7 M, whereas Total Assets are forecasted to decline to about 133.7 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Key indicators impacting Cabaletta Bio's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

6.72

7.08

Notably Down

Slightly volatile

Investors should never underestimate Cabaletta Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to research Cabaletta Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cabaletta Bio.

Net Income

(99.06 Million)

Build AI portfolio with Cabaletta Stock

Understanding current and past Cabaletta Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cabaletta Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Cabaletta Bio's assets may result in an increase in income on the income statement.

Please note, the presentation of Cabaletta Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cabaletta Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cabaletta Bio's management manipulating its earnings.

Cabaletta Bio Stock Summary

Cabaletta Bio competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US12674W1099
Business Address	2929 Arch Street,
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	www.cabalettabio.com
Phone	267 759 3100
Currency	USD - US Dollar

Cabaletta Bio Key Financial Ratios

	Return On Equity	-1.01
	EBITDA	(110.3 M)
	Net Income	(115.86 M)
	Cash Per Share	3.34 X
	Debt To Equity	(3.76) %

More Fundamentals

Cabaletta Bio Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	126.3M	117.0M	253.7M	185.0M	212.8M	133.7M
Other Current Liab	6.0M	4.8M	7.9M	12.2M	14.0M	14.7M
Net Tangible Assets	138.3M	109.5M	116.6M	104.5M	120.2M	84.0M
Net Debt	(122.2M)	(76.5M)	(188.2M)	(148.4M)	(133.5M)	(140.2M)
Retained Earnings	(112.6M)	(165.6M)	(233.2M)	(349.1M)	(314.2M)	(298.5M)
Accounts Payable	2.3M	2.5M	4.5M	4.9M	5.7M	5.9M
Cash	122.2M	81.6M	193.2M	164.0M	188.6M	114.4M
Total Liab	8.4M	12.4M	17.5M	32.7M	37.6M	39.5M
Net Invested Capital	118.0M	104.5M	236.2M	152.3M	175.2M	116.6M
Total Current Assets	124.5M	108.8M	244.5M	166.7M	191.7M	128.2M
Net Working Capital	116.2M	99.3M	228.5M	139.6M	160.5M	118.5M
Other Assets	357K	565K	1.0	(3.9M)	(3.5M)	(3.4M)
Other Current Assets	2.3M	2.3M	3.2M	2.7M	3.1M	3.1M

Cabaletta Bio Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	494K	733K	1.2M	748K	860.2K	433.5K
Operating Income	(46.3M)	(54.1M)	(74.7M)	(125.1M)	(112.6M)	(107.0M)
Ebit	(46.3M)	(54.1M)	(67.7M)	(115.1M)	(103.6M)	(98.4M)
Research Development	32.5M	39.3M	55.4M	97.2M	111.8M	117.4M
Ebitda	(45.6M)	(53.0M)	(66.2M)	(110.3M)	(99.3M)	(94.3M)
Income Before Tax	(46.3M)	(53.0M)	(67.7M)	(115.9M)	(104.3M)	(99.1M)
Net Income	(45.5M)	(51.8M)	(67.7M)	(115.9M)	(104.3M)	(99.1M)
Income Tax Expense	(1.8M)	(848K)	(757K)	(1.2M)	(1.0M)	(1.1M)
Net Interest Income	24K	1.2M	7.0M	9.3M	10.7M	11.2M
Interest Income	24K	1.2M	7.0M	10.0M	11.5M	12.1M
Gross Profit	(733K)	(3.7M)	(1.4M)	(4.8M)	(4.3M)	(4.1M)
Cost Of Revenue	733K	3.7M	1.4M	4.8M	5.5M	5.8M

Cabaletta Bio Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Investments	7.2M	(24.8M)	(22.5M)	47.3M	54.4M	57.1M
Change In Cash	20.8M	(40.6M)	111.6M	(29.3M)	(26.3M)	(25.0M)
Depreciation	733K	1.2M	1.4M	1.7M	2.0M	2.1M
Other Non Cash Items	62K	2.8M	1.3M	4.9M	5.6M	5.9M
Capital Expenditures	1.2M	2.5M	687K	2.2M	2.5M	2.7M
Net Income	(46.3M)	(53.0M)	(67.7M)	(115.9M)	(104.3M)	(99.1M)
End Period Cash Flow	122.2M	81.6M	193.2M	164.0M	188.6M	114.4M
Change To Netincome	2.3M	4.5M	5.9M	6.9M	6.2M	4.7M
Free Cash Flow	(35.3M)	(48.8M)	(54.2M)	(90.4M)	(81.4M)	(77.3M)

Cabaletta Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cabaletta Bio's current stock value. Our valuation model uses many indicators to compare Cabaletta Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cabaletta Bio competition to find correlations between indicators driving Cabaletta Bio's intrinsic value. More Info.

Cabaletta Bio is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers . At present, Cabaletta Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cabaletta Bio's earnings, one of the primary drivers of an investment's value.

Most indicators from Cabaletta Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cabaletta Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.The current year's Selling General Administrative is expected to grow to about 33.7 M, whereas Issuance Of Capital Stock is forecasted to decline to about 11.9 M.

	2023	2024	2025	2026 (projected)
Interest Income	7.0M	10.0M	11.5M	12.1M
Net Interest Income	7.0M	9.3M	10.7M	11.2M

Interest Income Net Interest Income

Cabaletta Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Other Assets	Other Current Assets	Deferred Long Term Liab	Property Plant And Equipment Net	Property Plant And Equipment Gross	Property Plant Equipment	Retained Earnings Total Equity
Total Assets		0.83	0.79	0.99	0.9	-0.97	-0.86	0.86	0.99	1.0	0.59	0.01	0.92	0.9	0.58	0.99	1.0	0.99	-0.89	-0.55	0.84	-0.33	0.69	0.71	0.83	-0.81
Other Current Liab	0.83		0.99	0.8	0.72	-0.83	-0.97	0.99	0.84	0.82	0.73	0.01	0.9	0.98	0.73	0.8	0.81	0.78	-0.69	-0.87	0.66	-0.71	0.95	0.96	0.81	-0.84
Total Current Liabilities	0.79	0.99		0.74	0.65	-0.77	-0.97	0.98	0.79	0.77	0.76	0.03	0.85	0.97	0.76	0.74	0.76	0.73	-0.6	-0.91	0.59	-0.74	0.98	0.99	0.8	-0.81
Total Stockholder Equity	0.99	0.8	0.74		0.92	-0.98	-0.82	0.83	0.98	0.99	0.55	-0.12	0.92	0.88	0.46	1.0	0.99	0.99	-0.91	-0.49	0.87	-0.31	0.64	0.66	0.8	-0.79
Net Tangible Assets	0.9	0.72	0.65	0.92		-0.93	-0.71	0.71	0.92	0.9	0.36	-0.14	0.92	0.78	0.36	0.92	0.91	0.91	-0.98	-0.42	0.94	-0.27	0.54	0.55	0.67	-0.71
Net Debt	-0.97	-0.83	-0.77	-0.98	-0.93		0.82	-0.84	-0.97	-0.97	-0.48	0.12	-0.93	-0.89	-0.47	-0.98	-0.97	-0.97	0.92	0.54	-0.89	0.38	-0.66	-0.68	-0.73	0.78
Retained Earnings	-0.86	-0.97	-0.97	-0.82	-0.71	0.82		-0.98	-0.84	-0.84	-0.79	-0.02	-0.89	-0.98	-0.73	-0.82	-0.83	-0.8	0.68	0.84	-0.62	0.58	-0.95	-0.96	-0.89	0.89
Accounts Payable	0.86	0.99	0.98	0.83	0.71	-0.84	-0.98		0.85	0.85	0.75	0.04	0.9	0.99	0.75	0.83	0.85	0.82	-0.69	-0.82	0.64	-0.68	0.94	0.95	0.86	-0.88
Cash	0.99	0.84	0.79	0.98	0.92	-0.97	-0.84	0.85		0.99	0.56	0.03	0.92	0.89	0.58	0.98	0.99	0.98	-0.89	-0.58	0.86	-0.34	0.68	0.7	0.79	-0.78
Cash And Short Term Investments	1.0	0.82	0.77	0.99	0.9	-0.97	-0.84	0.85	0.99		0.56	0.01	0.92	0.89	0.56	0.99	1.0	1.0	-0.89	-0.52	0.85	-0.32	0.67	0.69	0.81	-0.8
Common Stock Shares Outstanding	0.59	0.73	0.76	0.55	0.36	-0.48	-0.79	0.75	0.56	0.56		-0.15	0.56	0.71	0.47	0.55	0.55	0.5	-0.3	-0.71	0.24	-0.32	0.76	0.77	0.84	-0.68
Non Current Liabilities Total	0.01	0.01	0.03	-0.12	-0.14	0.12	-0.02	0.04	0.03	0.01	-0.15		-0.06	-0.02	0.67	-0.12	0.01	0.01	0.11	-0.06	-0.11	-0.05	0.04	0.03	-0.02	0.03
Capital Surpluse	0.92	0.9	0.85	0.92	0.92	-0.93	-0.89	0.9	0.92	0.92	0.56	-0.06		0.94	0.58	0.92	0.92	0.91	-0.92	-0.6	0.83	-0.51	0.77	0.79	0.82	-0.9
Other Stockholder Equity	0.9	0.98	0.97	0.88	0.78	-0.89	-0.98	0.99	0.89	0.89	0.71	-0.02	0.94		0.7	0.88	0.89	0.87	-0.76	-0.8	0.73	-0.65	0.92	0.93	0.85	-0.86
Total Liab	0.58	0.73	0.76	0.46	0.36	-0.47	-0.73	0.75	0.58	0.56	0.47	0.67	0.58	0.7		0.46	0.56	0.53	-0.35	-0.71	0.35	-0.59	0.76	0.76	0.58	-0.57
Net Invested Capital	0.99	0.8	0.74	1.0	0.92	-0.98	-0.82	0.83	0.98	0.99	0.55	-0.12	0.92	0.88	0.46		0.99	0.99	-0.91	-0.49	0.87	-0.31	0.64	0.66	0.8	-0.79
Total Current Assets	1.0	0.81	0.76	0.99	0.91	-0.97	-0.83	0.85	0.99	1.0	0.55	0.01	0.92	0.89	0.56	0.99		1.0	-0.9	-0.52	0.86	-0.32	0.66	0.69	0.81	-0.79
Net Working Capital	0.99	0.78	0.73	0.99	0.91	-0.97	-0.8	0.82	0.98	1.0	0.5	0.01	0.91	0.87	0.53	0.99	1.0		-0.91	-0.47	0.87	-0.31	0.62	0.65	0.77	-0.77
Short Long Term Debt Total	-0.89	-0.69	-0.6	-0.91	-0.98	0.92	0.68	-0.69	-0.89	-0.89	-0.3	0.11	-0.92	-0.76	-0.35	-0.91	-0.9	-0.91		0.32	-0.94	0.26	-0.49	-0.51	-0.65	0.73
Other Assets	-0.55	-0.87	-0.91	-0.49	-0.42	0.54	0.84	-0.82	-0.58	-0.52	-0.71	-0.06	-0.6	-0.8	-0.71	-0.49	-0.52	-0.47	0.32		-0.4	0.69	-0.92	-0.91	-0.6	0.55
Other Current Assets	0.84	0.66	0.59	0.87	0.94	-0.89	-0.62	0.64	0.86	0.85	0.24	-0.11	0.83	0.73	0.35	0.87	0.86	0.87	-0.94	-0.4		-0.31	0.48	0.49	0.51	-0.53
Deferred Long Term Liab	-0.33	-0.71	-0.74	-0.31	-0.27	0.38	0.58	-0.68	-0.34	-0.32	-0.32	-0.05	-0.51	-0.65	-0.59	-0.31	-0.32	-0.31	0.26	0.69	-0.31		-0.76	-0.75	-0.31	0.41
Property Plant And Equipment Net	0.69	0.95	0.98	0.64	0.54	-0.66	-0.95	0.94	0.68	0.67	0.76	0.04	0.77	0.92	0.76	0.64	0.66	0.62	-0.49	-0.92	0.48	-0.76		1.0	0.79	-0.76
Property Plant And Equipment Gross	0.71	0.96	0.99	0.66	0.55	-0.68	-0.96	0.95	0.7	0.69	0.77	0.03	0.79	0.93	0.76	0.66	0.69	0.65	-0.51	-0.91	0.49	-0.75	1.0		0.81	-0.78
Property Plant Equipment	0.83	0.81	0.8	0.8	0.67	-0.73	-0.89	0.86	0.79	0.81	0.84	-0.02	0.82	0.85	0.58	0.8	0.81	0.77	-0.65	-0.6	0.51	-0.31	0.79	0.81		-0.89
Retained Earnings Total Equity	-0.81	-0.84	-0.81	-0.79	-0.71	0.78	0.89	-0.88	-0.78	-0.8	-0.68	0.03	-0.9	-0.86	-0.57	-0.79	-0.79	-0.77	0.73	0.55	-0.53	0.41	-0.76	-0.78	-0.89

Click cells to compare fundamentals

Cabaletta Bio Account Relationship Matchups

Cabaletta Bio fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	126.3M	117.0M	253.7M	185.0M	212.8M	133.7M
Other Current Liab	6.0M	4.8M	7.9M	12.2M	14.0M	14.7M
Net Tangible Assets	138.3M	109.5M	116.6M	104.5M	120.2M	84.0M
Net Debt	(122.2M)	(76.5M)	(188.2M)	(148.4M)	(133.5M)	(140.2M)
Retained Earnings	(112.6M)	(165.6M)	(233.2M)	(349.1M)	(314.2M)	(298.5M)
Accounts Payable	2.3M	2.5M	4.5M	4.9M	5.7M	5.9M
Cash	122.2M	81.6M	193.2M	164.0M	188.6M	114.4M
Total Liab	8.4M	12.4M	17.5M	32.7M	37.6M	39.5M
Net Invested Capital	118.0M	104.5M	236.2M	152.3M	175.2M	116.6M
Total Current Assets	124.5M	108.8M	244.5M	166.7M	191.7M	128.2M
Net Working Capital	116.2M	99.3M	228.5M	139.6M	160.5M	118.5M
Other Assets	357K	565K	1.0	(3.9M)	(3.5M)	(3.4M)
Other Current Assets	2.3M	2.3M	3.2M	2.7M	3.1M	3.1M

Today, most investors in Cabaletta Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cabaletta Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cabaletta Bio growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.028)

At present, Cabaletta Bio's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Cabaletta Bio February 11, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cabaletta Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cabaletta Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cabaletta Bio based on widely used predictive technical indicators. In general, we focus on analyzing Cabaletta Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cabaletta Bio's daily price indicators and compare them against related drivers.

	Downside Deviation	4.33
	Information Ratio	0.0076
	Maximum Drawdown	32.87
	Value At Risk	(7.17)
	Potential Upside	8.16

Complementary Tools for Cabaletta Stock analysis

When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.

	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Transaction History View history of all your transactions and understand their impact on performance
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Cabaletta Bio Financials

Cabaletta Bio Balance Sheet Chart

Net Income

(99.06 Million)

Cabaletta Bio Stock Summary

Cabaletta Bio Key Financial Ratios

Cabaletta Bio Key Balance Sheet Accounts

Cabaletta Bio Key Income Statement Accounts

Cabaletta Bio Key Cash Accounts

Cabaletta Financial Ratios Relationships

Cabaletta Bio fundamental ratios Correlations

Cabaletta Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cabaletta Bio fundamental ratios Accounts

Price Earnings To Growth Ratio

(0.028)

Cabaletta Bio February 11, 2026 Opportunity Range

Complementary Tools for Cabaletta Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Total Current Assets

Other Stockholder Equity	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Net Invested Capital	- 0.98	Net Debt
Short Long Term Debt Total	- 0.98	Net Tangible Assets
Net Debt	- 0.98	Total Stockholder Equity
Net Working Capital	- 0.97	Net Debt